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Abstract
Background: Dementia is significant in Parkinson’s disease (PD) with personal and socioeconomic impact. Early identification of risk is of 
upmost importance to optimize management. Gait precedes and predicts cognitive decline and dementia in older adults. We aimed to evaluate 
gait characteristics as predictors of cognitive decline in newly diagnosed PD.
Methods: One hundred and nineteen participants recruited at diagnosis were assessed at baseline, 18 and 36 months. Baseline gait was 
characterized by variables that mapped to five domains: pace, rhythm, variability, asymmetry, and postural control. Cognitive assessment 
included attention, fluctuating attention, executive function, visual memory, and visuospatial function. Mixed-effects models tested independent 
gait predictors of cognitive decline.
Results: Gait characteristics of pace, variability, and postural control predicted decline in fluctuating attention and visual memory, whereas 
baseline neuropsychological assessment performance did not predict decline.
Conclusions: This provides novel evidence for gait as a clinical biomarker for PD cognitive decline in early disease.
Keywords: Biomarker—Dementia—Gait
Cognitive impairment is significant in Parkinson’s disease (PD) 
(1) with progression to PD dementia (PDD) highly prevalent in 
advanced disease (2). It significantly impacts on daily functioning 
and quality of life (3), and ultimately reduces life expectancy (4). 
Detecting “at risk” individuals in early disease is of upmost impor-
tance to optimize clinical management and progress novel therapeu-
tics. However, clinical biomarkers continue to be sought to address 
this unmet need.
Cognitive decline in PD is complex and the underlying patho-
physiology poorly understood. Deficits arise predominantly from 
dopaminergic and cholinergic dysfunction (5) which interact and 
impact selectively on different cognitive functions, yielding hetero-
geneous cognitive patient profiles (1). Because of this complexity, 
a single biomarker to predict cognitive decline and dementia in PD 
is unlikely to be sufficient; therefore, a combinatorial approach is 
considered optimal (5). Clinical biomarkers make an important con-
tribution to a combinatorial battery given the complexity, cost, and 
invasive nature of some laboratory or imaging biomarkers (5).
Gait has potential as a low-cost and noninvasive clinical bio-
marker for cognitive decline and dementia in PD based on findings 
which show gait changes precede and predict cognitive decline and 
dementia in ageing (6–8). Shared neurochemical and pathological 
mechanisms of gait and cognition explain this relationship and sup-
port the potential of gait characteristics as discrete clinical biomark-
ers of cognitive decline and dementia. Although there is a robust 
relationship between gait and cognition in early PD, a comprehen-
sive approach to the longitudinal nature of the relationship has yet 
to be established (9,10). Moreover, previous work lacks a consistent 
and detailed approach to evaluating gait characteristics, limiting 
interpretation (10,11).
This study utilized a comprehensive battery of gait and cognitive 
characteristics to determine (i) if gait can predict cognitive decline in 
early PD, (ii) if gait characteristics are global or specific predictors, 
and (iii) if gait is more sensitive than cognition in predicting cogni-
tive decline. Based on current literature (10) and our previous cross-
sectional work (9), we hypothesized that discrete gait characteristics 
will be sensitive to cognitive decline in early PD.
Methods
Participants
Subjects with newly diagnosed idiopathic PD were recruited 
to ICICLE-Gait, a nested study within Incidence of Cognitive 
Impairment in Cohorts with Longitudinal Evaluation-PD 
(ICICLE-PD) (12). Potential participants were recruited between 
June 2009 and December 2011. Idiopathic PD was diagnosed 
according to UK Parkinson’s disease Brain Bank Criteria. PD partici-
pants were assessed over three sessions (i) baseline, (ii) 18 months, 
and (iii) 36 months. PD exclusion criteria included; memory impair-
ment (≤24 Mini Mental State Exam [MMSE]), dementia with Lewy 
bodies, drug-induced Parkinsonism, vascular Parkinsonism, atypical 
Parkinson’s syndromes, poor English language, and inability to con-
sent. Participants were assessed “on” medication, defined as within 1 
hour of medication intake.
To provide a comparison of cognitive decline with normal age-
ing, controls of a similar age and sex were recruited from community 
sources. Two control cohorts were recruited; the first cohort com-
pleted assessments at sessions 1 and 3, the second cohort completed 
assessments at all time points. Inclusion criteria included: >60 years 
of age; able to walk independently without an aid; absent of cogni-
tive impairment (≤24 on MMSE) and absent of movement or mood 
disorders.
The study was approved by the Newcastle and North Tyneside 
Research and Ethics Committee.
Clinical Assessment
Age, sex, height, weight, and depression (using Geriatric Depression 
Scale [GDS-15]) were recorded at each session. The National Adult 
Reading Test (NART) assessed premorbid intelligence at baseline. 
PD motor severity was assessed using the Movement Disorders 
Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part 
III; Hoehn and Yahr Stage (H & Y); and levodopa equivalent daily 
dose (LEDD). Freezing of gait (FOG) was assessed with the FOG 
questionnaire. Comorbidities were self-reported by all participants.
Gait Assessment
Participants walked for 2 minutes at a comfortable pace around a 
25-m circuit inclusive of a 7 × 0.6m instrumented walkway (Platinum 
model GaitRite, CIR systems Inc, USA; Supplementary Figure 1). 
Gait assessment was completed under single task (ST) for which par-
ticipants were asked to “concentrate on their walking” and dual task 
(DT) where participants were asked to “concentrate equally on their 
walking and a concurrent task”. The Wechsler Forward Digit Span 
was adopted as the concurrent task; a validated working memory 
task tailored to individual performance. Maximum digit span was 
first assessed in sitting, determined by longest span recalled in two of 
three attempts. Participants then recalled continuous strings of their 
maximum digit span while walking (13).
Gait outcomes were derived from a model of gait developed in 
older adults (14) and validated in PD (15). The model describes 16 
discrete gait characteristics representing domains of pace, rhythm, 
variability, asymmetry, and postural control (Supplementary 
Figure 1).
Cognitive Assessment
A comprehensive cognitive battery was completed at all sessions. 
Individual tests were represented by seven cognitive domains. Global 
cognition: measured using the MoCA. Attention: Cognitive Drug 
Research battery (CDR); simple reaction time (SRT), choice reaction 
time (CRT), and digit vigilance (DV). Fluctuating attention (indi-
vidual reaction time variability): coefficient of variance (CV) of the 
SRT, CRT, and DV. Visual memory: Cambridge Neuropsychological 
Test Automated Battery (CANTAB); spatial recognition memory 
(SRM), pattern recognition memory (PRM), and paired associate 
learning (PAL). Executive-function: one touch stockings (OTS) from 
CANTAB, semantic fluency; naming animals in 90 seconds and the 
Hayling and Brixton (16). Visuospatial function: interlocking penta-
gon’s copying composite score from the MMSE. Working memory 
was assessed using Wechsler forward digit span (17). Additional ref-
erences are available in Supplementary Material.
Data Analysis
Analysis was conducted using SPSS (IBM Corp. V.21, USA) and R 
(R Foundation for Statistical Computing, V 3.2.2, Austria). The first 
stage was univariate to describe gait and cognitive data. Distribution 
of continuous variables was tested for normality using the Skewness–
Kurtosis test and inspection of boxplots and histograms. Paired sam-
ples t-test examined differences in baseline and final assessment for 
clinical characteristics. Student’s t-test and chi-square test examined 
differences between completers and noncompleters (p = .05).
The second stage of analysis used linear mixed effects modelling 
(LMEM; R, “lme4”) to model cognitive decline and its predictors. 
Random intercept models gave each participant a unique intercept 
and regression coefficient. Initially, univariate analysis was con-
ducted to determine cognitive assessments that significantly changed 
over time, those which changed significantly were entered into an 
adjusted model. The model was adjusted for covariates including 
baseline age, NART, and gender as fixed effects, as well as inter-
actions of session with GDS-15 and LEDD. A backward stepwise 
method was employed to remove nonsignificant covariates.
Third, LMEM identified baseline gait characteristics predictors of 
cognitive decline in PD. Cognitive decline was determined for each 
domain using the strongest representative of each domain, i.e., great-
est decline over time. Base models were constructed for each cognitive 
assessment (age, gender, NART, GDS-15, and LEDD), entered into the 
models as fixed effects. A backward stepwise method was employed. 
Gait characteristics under ST and DT at baseline were entered into 
the model as a fixed effect to determine whether gait characteristics in 
addition to covariates were a significant predictor of cognitive decline.
The final step identified whether baseline global cognition pre-
dicted change in cognition. MoCA and each gait characteristic at 
baseline were added to base models to assess which was a stronger 
predictor of cognitive decline. To further validate findings linear 
regression analysis was performed to identify whether baseline cog-
nitive measures could predict change in the same measure. For analy-
sis, cognitive change was the dependent variable with age, sex and 
NART entered in the first block and baseline cognition entered in 
the second block.
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Log-likelihood ratio tests compared model fit. Analyses were 
conducted without adjustment for multiple comparisons. A stringent 
p value of ≤.01 guided interpretations.
Results
Study Participants
Figure 1 summarizes participant recruitment and attrition in ICICE-
Gait. Initially, 150 PD participants were referred, of whom 127 con-
sented with 194 control subjects consented. After exclusions, 119 PD 
and 184 control subjects completed baseline assessment. At 18 months, 
106 (89%) PD and 72 (39%) control participants completed assess-
ments, at 36 months 81 (68%) PD and 118 (64%) control participants 
returned. Table 1 displays the clinical characteristics of participants at 
baseline and 36 months. The PD group contained proportionally more 
males throughout the study, whereas the control group contained pro-
portionally more females. Baseline comorbidities in both groups were 
low and largely similar between groups (Supplementary Table 1). The 
average PD disease duration at baseline was 6.29 ± 4.67 months. Over 
3 years, PD motor severity increased (p < .001) as did LEDD (p < .001). 
FOG significantly increased over 3 years (p < .001) but no participants 
experienced FOG during the gait assessment. Depression did not sig-
nificantly change in either group. There were no significant differences 
in clinical demographics for PD participants who did and did not com-
plete 36 month assessment (Supplementary Table 2).
Baseline Gait
PD baseline gait characteristics can be found in Supplementary 
Table  3. Comparing gait characteristics at baseline between 
completers and noncompleters, those who withdrew had higher step 
length variability under ST and DT (p =·.02 and p ≤ .01, respectively) 
and higher step velocity variability under DT only (p ≤ .01). There 
were no other significant differences (Supplementary Table 4).
Change in Cognition
Table  2 presents univariate and modelled change in cognition for 
both groups. Over 3 years, PD participants significantly declined on 
eight of 16 assessments. Attention declined on SRT (19.41 points 
per session [pps], p =·.01), CRT (36.65 pps, p < .01), and DV (8.89 
pps, p < .01). Fluctuating attention declined on CRT CV (1.29 pps, 
p < .01). PD participants declined on executive function; OTS (0.75 
pps, p < .01) and Brixton (0.31 pps, p < .01). Finally, PD participants 
declined on visual memory; SRM (0.71 pps, p < .01) and PAL (0.13 
pps, p  <  .01). Control participants declined on two of 16 assess-
ments; CRT (10.23 pps, p  <  .01) and SRM (0.37 pps, p  <  .01). 
Supplementary Table  5 presents all descriptive data for cognitive 
performance at each session. PD participants who withdrew before 
36 months had worse baseline working memory, attention, fluctuat-
ing attention, and visual memory (Supplementary Table 6).
Gait Predicts Cognitive Decline at 36 Months
ST and DT predictors were similar in nature, thus only ST data is 
presented (DT available in Supplementary Table 7). Table 3 sum-
marizes baseline ST gait predictors of cognitive decline. Decline 
in fluctuating attention was predicted by pace (slower veloc-
ity [β = 4.05, p < .01); reduced step length [β = 8.64, p < .01]), 
variability (increased swing time variability [β = 2.56, p < .01]; 
step stance variability [β  =  1.98, p =·.01]; and step length 
Figure 1. Flowchart of participants recruited and assessed throughout the ICICLE-Gait study.
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variability [β = 115.68, p < .01]), and gait-related postural con-
trol (increased step width [β = 26.69, p <  .01]). Visual memory 
decline was predicted by pace (reduced step length [β = 2.93, p 
=·01]). Prediction of decline in attention by variability was near 
significance (increased step length variability [β  =  1639.29, p 
=·04]) but decline in executive function was not predicted by any 
gait characteristic. All gait characteristics improved the fit of the 
model except for step width as a predictor of fluctuating atten-
tion decline (χ2 = 5.91, p =·.05).
Comparing Gait and Cognition as Predictors of 
Cognitive Decline
Compared to gait characteristics, baseline MoCA was a significant 
predictor of a decline in attention (p <  .01) but could not predict 
decline in fluctuating attention (p = .04) or visual memory (p = .15; 
Table 3).
For decline in fluctuating attention, characteristics of pace (step 
velocity [χ2 = 10.93, p < .01], step length [χ2 = 11.22, p < .01]) and 
variability (step length variability [χ2 = 8.75, p = .01]) proved bet-
ter predictors than MoCA. In addition, for visual memory decline 
pace (step velocity [χ2 = 8.70, p = .01] and step length [χ2 = 10.90, 
p  <  .01]) was a significant predictor over MoCA. However, other 
measures of pace (swing time variability [χ2 = 6.73, p =  .03]) and 
variability (stance time variability [χ2  =  7.11, p  =  .03]) did not 
improve model fit for decline in fluctuating attention, although these 
but not MoCA remained significant in the model. Additional linear 
regression analysis revealed baseline CRTCV was unable to predict 
CRTCV decline (p = .75; Supplementary Table 8).
Discussion
To our knowledge, this is the first study to demonstrate that gait is 
able to predict cognitive decline in early PD. Moreover, this was a 
large, incident cohort study followed from diagnosis allowing for 
prognostic significance of gait in early disease to be determined. Gait 
predicted decline in specific cognitive domains (fluctuating attention 
and visual memory) over 3 years which was selective to discrete gait 
characteristics. Importantly, gait was a stronger predictor than base-
line cognition. We therefore provide the first evidence for the utility 
of gait as a noninvasive clinical biomarker for early cognitive decline 
in PD.
Gait Predicts Cognitive Decline
Cognitive decline in fluctuating attention and visual memory was 
independently predicted by gait characteristics represented by 
domains of pace, variability, and postural control (15). Slower pace, 
higher gait variability, and more unstable postural control at diag-
nosis predicted decline in fluctuating attention. Additionally, slower 
pace predicted decline in visual memory. By comparison, character-
istics representing rhythm and asymmetry were unable to predict 
cognitive decline. Related evidence comes from robust associations 
between gait and cognition in cross-sectional studies in early PD (10) 
which supports our findings. Parallels can be drawn from studies 
in older adults showing prognostic associations between slow gait 
speed and increased gait variability with cognitive decline (6,7). 
In advanced PD, gait impairment on the MDS-UPDRS III predicts 
future PDD (11) further demonstrating the sensitivity of gait to cog-
nitive decline. However, in very early disease, tools with increased 
sensitivity are necessary to provide effective clinical biomarkers and 
derive novel therapeutics. Thus, highlighting the need for quantita-
tive gait analysis. Importantly, comprehensive gait analysis can be 
assessed in clinical practice with current technological advances 
improving future feasibility.
Progression of cognitive impairment over 36  months in our 
cohort was characterized by attention, fluctuating attention, exec-
utive-function, and visual memory similar to other incident cohorts 
(18,19). Muslimovic et al. observed greatest decline in attention and 
psychomotor speed (19). The Campaign study found visual memory 
and executive-function were early cognitive features to decline (18). 
Notably, this group did not assess attention; therefore, we cannot 
draw parallels with this domain.
Is Fluctuating Attention a Marker of Dementia?
We were able to predict change in fluctuating attention and visual 
memory, which is highly relevant given their contribution to cog-
nitive decline evolution and dementia in PD. Fluctuating attention 
was particularly sensitive to baseline gait. Previous work shows 
these cognitive features may be important precursors for PDD. For 
Table 1. Demographic Characteristics, Mean (SD), of Participants at Baseline and 36 Months
Demographic
PD Control
Baseline 36 Months T p Baseline 36 Months T p
Sex (M and F) 79 and 40 55 and 26 — — 78 and 106 53 and 64 — —
Age (years) 66.11 (9.90) 69.13 (9.90) −89.96 <.01 68.87 (7.10) 72.64 (7.06) 102.89 <.01
Height (m) 1.70 (.08) 1.69 (.09) 3.41 <.01 1.68 (0.10) 1.68 (0.09) −2.39 .02
NART 115.02 (11.13) — — — 117 (7.72) — — —
Disease duration (months) 6.29 (4.67) — — — — — — —
LEDD (mg/day) 172.26 (129.53) 515.05 (256.08) −12.94 <.01 — — — —
MDS-UPDRS III 24.97 (10.44) 38.04 (12.50) −11.33 <.01 — — — —
FOG 0.59 (2.54) 2.18 (5.33) −2.71 <.01 — —
GDS 2.59 (2.23) 2.80 (2.41) −0.89 .38 1.28 (2.03) 1.41 (2.34) −0.71 .48
Hoehn and Yahr stage, n (%) I (28) I (1) — — — — — —
II (70) II (82)
III (21) III (9)
IV (0) IV (2)
Note: FOG = freezing of gait; GDS = geriatric depression scale; LEDD = levodopa equivalent daily dose; MDS-UPDRS III = unified Parkinson’s disease rating 
scale; NART = national adult reading test; PD, Parkinson’s disease. Bold values represent significance level p ≤ 0.01.
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example, fluctuating attention (measured by CRT SD) is signifi-
cantly worse in Lewy body dementias (an overarching term com-
prising both PDD and DLB) compared to Alzheimer's disease (AD) 
(20). Critically, variability on CRT most strongly reflects fluctuating 
cognition in DLB (21). Visual and memory components play a vital 
role in SRM which is temporally mediated; however, lesion (22) and 
cognitive cohort studies (23) suggest frontal involvement, indicating 
overlap of underlying mechanisms.
Potential Underlying Mechanisms
Underlying pathology of gait and cognition is poorly understood 
but evidence suggests they share common substrates. Gait is not 
purely dopaminergic (24) and interacts with other neurotransmit-
ter systems. Previous work implicates the cholinergic system in gait 
dysfunction, demonstrated by short-latency afferent inhibition (25) 
and intervention (26) studies. The cholinergic system also has an 
essential role in attention (27) likely to stem from nucleus basalis of 
Meynert (nbM) (27,28), which may also mediate visual deficits (28). 
Additionally, the role of amyloid pathology in early gait impairment 
in PD (29) demonstrates a combination of pathological substrates of 
gait and cognitive decline.
Interestingly, gait was unable to predict executive-function 
decline, an early feature of cognitive decline (18). This may reflect 
the overarching role of attention in mediating cognitive function 
(30), or sensitivity of attentional over executive-function measures 
in early disease.
Comparison of Gait and Cognitive Outcomes
We were also interested to see if discrete gait characteristics were 
more sensitive than cognitive measures to early cognitive decline. Our 
findings suggest that this is the case. Global cognition did not pre-
dict decline in fluctuating attention or visual memory. Furthermore, 
additional analysis showed that fluctuating attention did not predict 
future cognition decline. These findings strengthen the case for the 
role of discrete gait characteristics as predictors of cognitive decline 
in early PD.
We extended knowledge of gait as a prognostic marker by tak-
ing a comprehensive measurement approach which highlighted the 
specificity of gait to cognitive decline. We also evaluated gait under 
DT because it sensitizes the relationship between cognition and gait 
and is frequently incorporated into protocols. In contrast to earlier 
work (31), our DT cognitive associations were not significantly dif-
ferent from older adults, partly reflecting our DT paradigm which 
controls for baseline cognitive capacity (13).
Limitations
This study has several limitations. First, although our cognitive battery 
was comprehensive for attention, executive function, and memory, we 
acknowledge that not all aspects of these domains were assessed. Our 
cognitive battery was also less comprehensive for visuospatial func-
tion. Significant visuospatial decline was not apparent in our cohort 
but other work identified pentagons decline in early PD (18) suggest-
ing this assessment was adequate. Second, the longitudinal nature of 
the study inevitably leads to attrition. Attrition rates totaled 32%, 
comparable to similarly designed studies (18,19). Baseline scores 
revealed that those who withdrew were worse on cognitive assess-
ments (Supplementary Table 3). This may indicate those with more 
rapid decline were more likely to withdraw and would have been of 
interest to this study. In an attempt to alleviate bias, LMEM were cho-
sen as this technique is able to handle missing data yet it is possible 
rate of cognitive decline was underestimated. Thirdly, the population 
was drawn from an incident PD cohort followed from diagnosis with 
repeat assessments every 18 months. Although misdiagnosis may have 
contributed, this is unlikely to have made a major impact. Diagnosis 
followed a stringent process, applying the Queen’s Square Brain Bank 
Criteria at each assessment, and revised diagnosis revealed that the 
numbers were low. In addition, the bidirectional relationship between 
gait and cognition should be acknowledged. A number of studies have 
explored this relationship in older adults (32) but not in PD (10); how-
ever, this was beyond the scope of the present study. Finally, our find-
ings need to be replicated in an independent cohort.
Conclusions
This is the first study to identify gait as a predictor of cognitive 
decline in a large incident PD cohort. Furthermore, it was identi-
fied that gait is sensitive to decline in specific cognitive domains in 
Table 3. LMEM Identifying Single Task Gait Characteristics and Global Cognition as Predictors of Cognitive Decline in PD
Cognitive domain Cognitive assessment Predictor domain Predictor
Regression coefficients
β SE T p
Gait Attention CRT Variability Step length SD × session 1639.29 807.78 2.10 .04
Fluctuating attention CRTCV Pace Step velocity × session −4.05 1.34 −3.02 <.01
Step length × session −8.64 2.86 −3.02 <.01
Step swing SD × session 2.56 0.93 2.75 <.01
Variability Step time SD × session 2.14 0.90 2.38 .02
Step stance SD × session 1.98 0.77 2.58 .01
Step length SD × session 115.68 40.41 2.86 <.01
Rhythm Step stance time × session 0.01 0.03 2.26 .03
Postural control Step width × session 26.69 9.02 2.96 <.01
Visual memory SRM Pace Step velocity × session 1.32 0.56 2.33 .02
Step length × session 2.93 1.19 2.47 .01
Cognition Attention CRT Global cognition MoCA × session −5.68 1.54 −3.70 <.01
Fluctuating attention CRTCV −1.68 0.80 −2.10 .04
Visual memory SRM 0.05 0.03 1.45 .15
Note: CRT = choice reaction time; CV = coefficient of variance; MoCA = Montreal cognitive assessment; SD = standard deviation; SE = standard error; SRM = 
spatial recognition memory. Bold values represent significance level p ≤ 0.01.
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PD. Our work focused on specific assessments of cognitive decline, a 
critical approach providing further understanding of the underlying 
pathology of gait and cognition. Future work will focus on gait as a 
predictor of PDD as the cohort evolves.
Supplementary Material
Supplementary data is available at The Journals of Gerontology, 
Series A: Biological Sciences and Medical Sciences online.
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